Pattern (Discovery Tools) key facts
as of Oct 2026- Provider of single-cell microbiology antimicrobial treatment intended to simplify antibiotic selection for life-threatening infections.
- Pattern (Discovery Tools) is valued at approximately $105.0M as of Oct 2026 (last reported valuation).
- It has raised $92.1M; the latest was Later Stage VC ($44.2M) in Aug 2025.
- Notable investors include Siparex, Illumina Ventures, CoInvest Capital, CARB-X, Concorde Investment Management — 8 tracked in total.
- Status: Privately Held (backing).
Pattern (Discovery Tools)'s last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·Watch Pattern (Discovery Tools): the Monday email on marks, rounds and moves
Pattern (Discovery Tools) funding rounds
No funding rounds for Pattern (Discovery Tools) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pattern (Discovery Tools)
8Pattern (Discovery Tools) valuation
Pattern (Discovery Tools)'s last reported valuation was $105 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Pattern (Discovery Tools) investors
8 investors are on record for Pattern (Discovery Tools), including Siparex, Illumina Ventures, CoInvest Capital and CARB-X.
About Pattern (Discovery Tools)
Provider of single-cell microbiology antimicrobial treatment intended to simplify antibiotic selection for life-threatening infections. The company includes antibiotic selection through a lab test that uses single-cell analysis technology to shorten test time by zooming in and measuring the live response of each pathogenic cell directly, enabling doctors to improve patient outcomes and slow down the emergence of bacteria that are resistant to existing antibiotics.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2016
- Employees
- 45
- Website
- pattern.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.